Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Summary
Tirzepatide is a dual agonist of GLP-1 Receptor and the GIP receptor, producing substantial improvement in glycaemic control, weight reduction and insulin sensitivity. Beyond its metabolic effects, incretin signalling has demonstrated neuroprotective and neurotropic properties, including activation of intracellular pathways that enhance neuronal survival and regeneration. Using tirzapatide for diabetic sensorimotor peripheral neuropathy and assessing with CCM / NCS and BDNF will represent three complementary aspects of nerve regeneration: metabolic control, structural nerve repair and neurotrophic signalling.
Official title: Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy: A Randomized, Open Label, Controlled Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-07
Completion Date
2028-07-01
Last Updated
2026-07-15
Healthy Volunteers
No
Conditions
Interventions
Tirzepatide 2.5mg weekly
tirzepatide will be initiated at 2.5 mg weekly and dose will be escalated to 7.5 mg weekly depending upon tolerance and changes in parameters from baseline as described as outcomes
all standard of care to diabetic patient besides tirzepatide
diabetic patient will receive all standard of care beside tirzepatide